Acceptability of short message service (SMS) as a tool for malaria treatment adherence in the Brazilian Amazon: a qualitative study

Background: Malaria is one of the leading causes of morbidity worldwide, and patient adherence to prescribed antimalarials is essential for effective treatment. Methods: This cross-sectional study, with in-depth telephone interviews, analyzed participants’ perceptions of short message service (SMS) in adherence to treatment. Results: Five thematic categories emerged: decreased forgetfulness, the novelty of the tool, easy-to-understand language, the impact of SMS messages during treatment, and suggestions for improvement and complaints. Conclusions: SMS could assist patients in adhering to prescribed antimalarials.Fil: Rodovalho, Sheila. Universidade do Estado do Amazonas; BrasilFil: Dias, Ádila Liliane Barros. Universidade do Estado do Amazonas; BrasilFil: Paz Ade, Maria. Pan American Health Organization; ArgentinaFil: Saint Gerons, Diego Macias. Pan American Health Organization; ArgentinaFil: Castro, Jose Luis. Pan American Health Organization; ArgentinaFil: Beratarrechea, Andrea Gabriela. Instituto de Efectividad Clínica y Sanitaria; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Murta, Felipe Leão Gomes. Universidade do Estado do Amazonas; BrasilFil: dos Santos, Alicia Cacau Patrine. Universidade do Estado do Amazonas; BrasilFil: Marques, Leonardo Lincoln Gomes. Universidade do Estado do Amazonas; BrasilFil: Sampaio, Vanderson Souza. Universidade do Estado do Amazonas; BrasilFil: Baia da Silva, Djane Clarys. Fundación Oswaldo Cruz; Brasil. Universidade do Estado do Amazonas; BrasilFil: Monteiro, Wuelton Marcelo. Universidade do Estado do Amazonas; Brasi

Additional file 1 of Factors associated to the presence of headache in patients with influenza infection and its consequences: a 2010–2020 surveillance-based study

Additional file 1: Supplementary table 1. Surveyed population per age-group. Supplementary table 2. Number of cases per season during the entire study period

Trends in attention-deficit hyperactivity disorder medication use:a retrospective observational study using population-based databases

BACKGROUND: The use of medications to treat attention deficit hyperactivity disorder (ADHD) has increased, but the prevalence of ADHD medication use across different world regions is not known. Our objective was to determine regional and national prevalences of ADHD medication use in children and adults, with a specific focus on time trends in ADHD medication prevalence. METHODS: We did a retrospective, observational study using population-based databases from 13 countries and one Special Administrative Region (SAR): four in Asia and Australia, two in North America, five in northern Europe, and three in western Europe. We used a common protocol approach to define study populations and parameters similarly across countries and the SAR. Study populations consisted of all individuals aged 3 years or older between Jan 1, 2001, and Dec 31, 2015 (dependent on data availability). We estimated annual prevalence of ADHD medication use with 95% CI during the study period, by country and region and stratified by age and sex. We reported annual absolute and relative percentage changes to describe time trends. FINDINGS: 154.5 million individuals were included in the study. ADHD medication use prevalence in 2010 (in children aged 3-18 years) varied between 0.27% and 6.69% in the countries and SAR assessed (0.95% in Asia and Australia, 4.48% in North America, 1.95% in northern Europe, and 0.70% in western Europe). The prevalence of ADHD medication use among children increased over time in all countries and regions, and the absolute increase per year ranged from 0.02% to 0.26%. Among adults aged 19 years or older, the prevalence of any ADHD medication use in 2010 varied between 0.003% and 1.48% (0.05% in Asia and Australia, 1.42% in North America, 0.47% in northern Europe, and 0.03% in western Europe). The absolute increase in ADHD medication use prevalence per year ranged from 0.0006% to 0.12%. Methylphenidate was the most commonly used ADHD medication in most countries. INTERPRETATION: Using a common protocol and data from 13 countries and one SAR, these results show increases over time but large variations in ADHD medication use in multiple regions. The recommendations of evidence-based guidelines need to be followed consistently in clinical practice. Further research is warranted to describe the safety and effectiveness of ADHD medication in the short and long term, and to inform evidence-based guidelines, particularly in adults. FUNDING: None